Myovant Sciences Ltd. develops innovative treatments for men and women, including relugolix, a medication that aids in the treatment of heavy menstrual bleeding, endometriosis-associated pain, and advanced prostate cancer. MVT-602 is also in development, which helps with female infertility for those undergoing assisted reproduction. They collaborate with Pfizer Inc. and is a London-based subsidiary of Sumitovant Biopharma Ltd.